Effect of low-irritant formulation on adherence to growth hormone therapy in pediatric patients with short statue: An exploratory retrospective observational study.

Effect of low-irritant formulation on adherence to growth hormone therapy in pediatric patients with short statue: An exploratory retrospective observational study. - GTL-Adherence

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041833

Enrollment

Registered

2020-09-18

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Short statue caused by growth hormone deficiency, Turner syndrome, or SGA (born small for gestational age)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Treatment-naive at the start of GH therapy. -Aged 3 years or older at the start of GH therapy. -Using Growjector-L. -Started GH therapy between September 1, 2017 and January 31, 2021. -Written informed consent from a legally acceptable representative of the patient, along with informed assent if applicable.

Exclusion criteria

Exclusion criteria: -Contraindications for GH therapy. eg, Diabetes, malignancy, (possible) pregnancy. -Judgement of physicians.

Design outcomes

Primary

Measure	Time frame
Medication adherence of patients administered new or old formulation of Growject in daily clinical practice.	—

Secondary

Measure	Time frame
-Patients characteristics. -Time course change in medication adherence. -Nonadherence-free survival. -Exploration on factors affecting adherence to GH therapy.	—

Countries

Japan

Contacts

Public ContactKei Takasawa

Tokyo Medical and Dental University Department of Pediatrics and Developmental Biology

ktakasawa.ped@tmd.ac.jp03-3813-6111

Outcome results